Comparison of Liver Disease in Patients Before and During the COVID-19 Pandemic Who were Admitted to the General Hospital of the University of Muhammadiyah Malang


COVID-19-associated liver injury is defined as any liver damage that occured during during the course of infection and treatment of COVID-19 patients, with or without preexisting liver disease. This includes a broad spectrum of potential pathomechanisms, including direct cytotoxicity from active viral replication of SARS-CoV-2 in the liver and immune-mediated liver damage due to the severe inflammatory response/ systemic inflammatory response syndrome (SIRS) in COVID-19. Data was taken from 206 patients with COVID-19 who were admitted to our hospital and were examined physically. Laboratory and ultrasound results showed abnormal rates associated with liver disease. The four-year study was conducted from January 2018 to December 2021. 116 pts were collected in the period 2018 to 2019 (2 years precov) and 90 pts 2 years (2020-2021) in the era of the COVID-19 pandemic. Women’s precov was 60 pts and dcov was 30 pts, while men showed 56 pts and 60 pts precov during COVID-19 infection. Liver cirrhosis was 28 pts precov and 41 pts dcov, followed by NSRH 25 pts precov and 12 pts dcov, NASH 24 pts precov and 6 pts dcov, Hep. B 20 precov and 10 dcov, acute viral hepatitis 12 precov and 16 dcov points. In total liver cirrhosis placed the first rank 69 pts (33, 5%). Followed by NSRH 17, 96 %; NASH 14, 56%, B. Hep. 14, 56 % and Ac.viral Hep. 13, 59%.

Keywords: pre-during pandemic covid-19, liver disease, liver cirrhosis

[1] Nardo AD, Schneeweiss-Gleixner M, Bakail M, Dixon ED, Lax SF, Trauner M. Pathophysiological mechanisms of liver injury in COVID-19. Liver Int. 2021 Jan;41(1):20–32.

[2] Wang Y, Liu S, Liu H, Li W, Lin F, Jiang L, et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol. 2020 Oct;73(4):807–16.

[3] Kucharski AJ, Russell TW, Diamond C, Liu Y, Edmunds J, Funk S, et al.; Centre for Mathematical Modelling of Infectious Diseases COVID-19 working group. Early dynamics of transmission and control of COVID-19: a mathematical modelling study. Lancet Infect Dis. 2020 May;20(5):553–8.

[4] Kumar P, Sharma M, Kulkarni A, Rao PN. Pathogenesis of Liver Injury in Coronavirus Disease 2019 [Internet]. J Clin Exp Hepatol. 2020;10(6):641–2.

[5] Nassir F, Rector RS, Hammoud GM, Ibdah JA. . Gastroenterol Hepatol (N Y). 2015;11(3):167–75.

[6] Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999 Jun;116(6):1413–9.

[7] Mott J, Morrison JA. Small animal gastrointestinal diseases. Blackwell’s Five-Minute Veterinary Consult Clinical Companion. 2019. 1–979 p.

[8] Gastroenterol WJ. Contents. 2021;9327(5).

[9] Bourgonje AR, Abdulle AE, Timens W, Hillebrands JL, Navis GJ, Gordijn SJ, et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J Pathol. 2020 Jul;251(3):228–48.

[10] Machhi J, Herskovitz J, Senan AM, Dutta D, Nath B, Oleynikov MD, et al. The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections. J Neuroimmune Pharmacol. 2020 Sep;15(3):359–86.

[11] loganathan S, Kuppusamy M, Wankhar W, Gurugubelli KR, Mahadevappa VH, Lepcha L, et al. Angiotensin-converting enzyme 2 (ACE2): COVID 19 gate way to multiple organ failure syndromes. Respir Physiol Neurobiol [Internet]. 2021;283:103548. Available from:

[12] Lizardo-Thiebaud MJ, Cervantes-Alvarez E, Limon-de la Rosa N, Tejeda-Dominguez F, Palacios-Jimenez M, Méndez-Guerrero O, et al. Direct or Collateral Liver Damage in SARS-CoV-2-Infected Patients. Semin Liver Dis. 2020 Aug;40(3):321–30.

[13] Chai X, Hu L, Zhang Y, Han W, Lu Z, Ke A, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv [Internet]. 2020.

[14] Dey A, Sen S, Maulik U. Unveiling COVID-19-associated organ-specific cell types and cell-specific pathway cascade. Brief Bioinform. 2021 Mar;22(2):914–23.

[15] Shi H, Wang W, Yin J, Ouyang Y, Pang L, Feng Y, et al. The inhibition of IL-2/IL-2R gives rise to CD8+ T cell and lymphocyte decrease through JAK1-STAT5 in critical patients with COVID-19 pneumonia [Internet]. Cell Death Dis. 2020 Jun;11(6):429.

[16] Fara A, Mitrev Z, Rosalia RA, Assas BM. Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines. Open Biol. 2020 Sep;10(9):200160.

[17] Gupta R, Misra A. Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infectionwith reference to use of therapeutic and other drugs used in Co-morbid diseases (Hypertension, diabetes etc) [Internet]. Diabetes Metab Syndr. 2020;14(3):251–4.

[18] Lei P, Zhang L, Han P, Zheng C, Tong Q, Shang H, et al. Liver injury in patients with COVID-19: clinical profiles, CT findings, the correlation of the severity with liver injury. Hepatol Int. 2020 Sep;14(5):733–42.

[19] Singh S, Khan A. Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Among Patients With Preexisting Liver Disease in the United States: A Multicenter Research Network Study [Internet]. Gastroenterology. 2020 Aug;159(2):768–771.

[20] Mantovani A, Beatrice G, Dalbeni A. Coronavirus disease 2019 and prevalence of chronic liver disease: A meta-analysis. Liver Int. 2020 Jun;40(6):1316–20.